DKTK-Studienregister

DetailsucheDetailsuche
Klicken Sie auf Detailsuche, um z.B. nach Therapielinie, molekularem Marker oder Rekrutierungsstatus zu suchen.
FreitextsucheFreitextsuche
Sie können hier nach dem Studienkurzcode oder einem Teil des Studientitels suchen.
Studienauswahl
Zentren
Status der Studie

» Urogenitale Tumoren » Blasenkarzinom

Alle Linien

Bayer 19131
Phase 1b/2 study of rogaratinib (BAY 1163877) in combination with atezolizumab in urothelial carcinoma (Aktiv)

CheckMate901
Study of Nivolumab in Combination With Ipilimumab or Standard of Care Chemotherapy Compared to the Standard of Care Chemotherapy Alone in Treatment of Patients With Untreated Inoperable or Metastatic Urothelial Cancer (CheckMate901) (Aktiv)

RACE IT
Radio-Immunotherapy Before Cystectomy in Locally Advanced Urothelial Carcinoma of the Bladder (RACE IT) (Aktiv)

Erstlinie

ABACUS
Preoperative MPDL3280A in Transitional Cell Carcinoma of the Bladder (Aktiv)

MK-3475-905
Randomisierte Phase-3-Studie zur Bewertung der Zystektomie mit perioperativer Pembrolizumab und Zystektomie mit perioperativem Enfortumab Vedotin und Pembrolizumab versus Zystektomie allein bei Cisplatin-ineligiblen Teilnehmern mit muskelinvasiver Blase Krebs (KEYNOTE-905/EV-303) (Aktiv)

Zweitlinie oder später

AArau-Studie
A Phase IIB study of the tetramodal therapy of T2-T4 Nx MO bladder cancer with hyperthermia combined with chemoradiotherapy following TUR-BT (Aktiv)

BAY 17403
This is a randomized, open-label, multicenter Phase 2/3 study to evaluate the efficacy and safety of rogaratinib (BAY 1163877) compared to chemotherapy in patients with FGFRpositive locally advanced or metastatic urothelial carcinoma who have received Prior platinum-containing chemotherapy (Aktiv)

BMS CA017078
A study of Chemo only versus Chemo plus Nivo with or without BMS-986205, Followed by Post- Surgery Therapy with Nivo or Nivo and BMS-986205 in Patients with MIBC (Aktiv)

CNIR178X2201
Study of efficacy and safety of NIR178 and PDR001 combination in patients with selected solid tumors and non-Hodgkin lymphoma (Aktiv)

CabUC
Cabozantinib in Patients With Locally Advanced or Metastatic Urothelial Cell Carcinoma. (Aktiv)

CheckMate901
Study of Nivolumab in Combination With Ipilimumab or Standard of Care Chemotherapy Compared to the Standard of Care Chemotherapy Alone in Treatment of Patients With Untreated Inoperable or Metastatic Urothelial Cancer (CheckMate901) (Aktiv)

GEM3PSCA-01
Study With Bispecific Antibody Engaging T-cells, in Patients With Progressive Cancer Diseases With Positive PSCA Marker (Aktiv)

GO39733
This is a Phase 1a/1b, open-label, multicenter, global, dose-escalation study designed to evaluate the safety, tolerability, immune response, and pharmacokinetics of RO7198457 as a single agent and in combination with atezolizumab (MPDL3280A, an engineered anti-programmed death-ligand 1 [anti-PD-L1] antibody). (Aktiv)

DKTK-Studienregister
Dr. N. Gökbuget, Dipl.-Biol. K. Ihrig | Ohne Gewähr für Richtigkeit oder Vollständigkeit | ccp@dkfz.de